GALECTO BIOTECH ApS
CVR 34878366 · Private limited company (ApS) · Active · Medium risk
GALECTO BIOTECH ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 14 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 7.8m and a net result of DKK -709k. CEO: Garrett Michael Winslow.
Bankruptcy risk for GALECTO BIOTECH ApS
1.0 × the average (1.41%) · higher risk than 75% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 34878366
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (13 years)
- Address
- c/o Symbion, Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 80k
- Employees
- 3 (2018)
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 2 of 14 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 96.8% |
| Current ratio | 3,399% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 1 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK 1.0m | DKK 5.5m |
| Net profit | DKK -709k | DKK 310k |
| Equity | DKK 7.8m | DKK 8.6m |
| Total assets | DKK 8.1m | DKK 8.9m |
| Cash | DKK 1.0m | – |
| Short-term debt | DKK 238k | – |
| Avg. employees | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · EY.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 202 | Late | |
| 1 Jan 2024 – 31 Dec 2024 | 161 | ||
| 1 Jan 2023 – 31 Dec 2023 | 85 | ||
| 1 Jan 2022 – 31 Dec 2022 | 75 | ||
| 1 Jan 2021 – 31 Dec 2021 | 90 | ||
| 1 Jan 2020 – 31 Dec 2020 | 159 | ||
| 1 Jan 2019 – 31 Dec 2019 | 262 | Late | |
| 1 Jan 2018 – 31 Dec 2018 | 93 | ||
| 1 Jan 2017 – 31 Dec 2017 | 152 | ||
| 1 Jan 2016 – 31 Dec 2016 | 20 | ||
| 1 Jan 2015 – 31 Dec 2015 | 105 | ||
| 1 Jan 2014 – 31 Dec 2014 | 163 | ||
| 1 Jan 2013 – 31 Dec 2013 | 157 | ||
| 3 Dec 2012 – 31 Dec 2012 | 155 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Garrett Michael Winslow | Current | |
| Board | Hans Thalsgård Schambye | ||
| Board | Jonathan Paul Freve | ||
| Board | Anders Hjelholt Pedersen | ||
| Board | Bertil Erik Lindmark | ||
| Board | Hans Thalsgård Schambye | ||
| Board | Garrett Michael Winslow | ||
| Owner (100%) | Galecto Biotech AB | Current | |
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | ATHOS STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | AIDER Godkendt Revisionsaktieselskab | ||
| Founder | Hans Thalsgård Schambye | Current |
Address history (1 moves)
| c/o Symbion, Nordre Fasanvej 215, 2000 Frederiksberg | |
| c/o Cobis A/S, Ole Maaløes Vej 3, 2200 København N |
Employees per year
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Catalyst Vaccination A/S Frederiksberg
- RefuelBio ApS Frederiksberg
- BioMomentum Advisors ApS Frederiksberg
- Oak Mountain Consulting ApS Frederiksberg
- Biotinia ApS Frederiksberg
- Nordic BioVentures ApS Frederiksberg C
- Zevra Denmark A/S Frederiksberg
- BioPhenyx ApS Frederiksberg
- BioSpringbok ApS Frederiksberg
- Orbis Medicines ApS Frederiksberg
- Epoqe Pharma ApS Frederiksberg
- SJM IP ApS Frederiksberg C
Questions and answers about GALECTO BIOTECH ApS
Has GALECTO BIOTECH ApS gone bankrupt?
No, GALECTO BIOTECH ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of GALECTO BIOTECH ApS?
Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.
Who is the CEO of GALECTO BIOTECH ApS?
Garrett Michael Winslow is the CEO of GALECTO BIOTECH ApS.
Who is the auditor of GALECTO BIOTECH ApS?
GALECTO BIOTECH ApS most recently used EY Godkendt Revisionspartnerselskab.
When was GALECTO BIOTECH ApS founded?
GALECTO BIOTECH ApS was founded on 3 December 2012.
What is the equity of GALECTO BIOTECH ApS?
Equity was DKK 7.8m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.